TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37642035

Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to help participants with PAD lose weight and walk for exercise
Number of subjects: 212

Group type: COMPARATOR
Intervention: Walking exercise alone
Number of subjects: 212
Study: 37642118

Group type: EXPERIMENTAL
Intervention: Baseline step count
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Baseline dyspnoea
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Decreased lung function and MVPA from baseline to 2 weeks
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Baseline physical activity (PA) and dyspnoea
Number of subjects: 419
Study: 37642160

Group type: EXPERIMENTAL
Intervention: FibroTest-T2D
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: VCTE
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: TD-SWE
Number of subjects: 402

Group type: COMPARATOR
Intervention: Fibrosis-4
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: MashTest-T2D
Number of subjects: 402

Group type: COMPARATOR
Intervention: Aspartate aminotransferase
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: SteatoTest-T2D
Number of subjects: 402

Group type: COMPARATOR
Intervention: Controlled attenuation parameter
Number of subjects: 402

Group type: COMPARATOR
Intervention: Hepatorenal gradient
Number of subjects: 402
Study: 37642248

Group type: EXPERIMENTAL
Intervention: Oxytocin only
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Oxytocin plus intrauterine misoprostol
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Carbetocin only
Number of subjects: 156
Study: 37642285

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 6811

Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 6811

Group type: COMPARATOR
Intervention: Robotic-assisted hysterectomy (RH)
Number of subjects: 6811

Group type: COMPARATOR
Intervention: Vaginal natural orifice hysterectomy (V-NOTES)
Number of subjects: 6811
Study: 37642347

Group type: EXPERIMENTAL
Intervention: Logotherapy-based, nurse-guided meaning attribution conversations (MACs), 7 sessions
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 68
Study: 37642608

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2732
Study: 37642625

Group type: EXPERIMENTAL
Intervention: Active taVNS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham taVNS
Number of subjects: 24
Study: 37642628

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 269
Study: 37642679

Group type: EXPERIMENTAL
Intervention: ACT™ periurethral adjustable balloons
Number of subjects: 13
Study: 37642787

Group type: EXPERIMENTAL
Intervention: LDCT screening
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Risk-based screening
Number of subjects: 48
Study: 37642966

Group type: EXPERIMENTAL
Intervention: Group-based prenatal care (GPNC) with 10 group-based sessions
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Individual prenatal care (IPNC)
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Group-based prenatal care (GPNC) among participants with GD
Number of subjects: 2348
Study: 37643290

Group type: EXPERIMENTAL
Intervention: Combination HIV prevention strategies implemented at the community level
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Community-level measures reflecting sexual behaviour and socio-economic make-up
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Prevalence of detectable virus (PDV) at 2 years
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Individual-level factors such as socio-economic status, AUDIT score, medical male circumcision, and certain sexual behaviours
Number of subjects: 2000
Study: 37643299

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37643308

Group type: EXPERIMENTAL
Intervention: Teleconsultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37643314

Group type: EXPERIMENTAL
Intervention: Extracorporeal cell-directed immunomodulatory device (selective cytopheretic device)
Number of subjects: 2
Study: 37643373

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 128

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 128
Study: 37643378

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 41
Study: 37643382

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg once every 3 weeks) combined with bevacizumab and six cycles of chemotherapy doublet
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo combined with bevacizumab and six cycles of chemotherapy doublet
Number of subjects: 614
Study: 37643392

Group type: EXPERIMENTAL
Intervention: Weekly phone counseling sessions with bidirectional text messages
Number of subjects: 425

Group type: COMPARATOR
Intervention: Weekly phone counseling sessions with unidirectional text messages
Number of subjects: 425
Study: 37643414

Group type: EXPERIMENTAL
Intervention: Sankofa Pediatric HIV disclosure intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disclosed group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Undisclosed group
Number of subjects: 0
Study: 37643520

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: LDL-C Q1 (≤1.76 mmol/L)
Number of subjects: 209

Group type: COMPARATOR
Intervention: LDL-C Q2 (1.77-2.36 mmol/L)
Number of subjects: 209

Group type: COMPARATOR
Intervention: LDL-C Q3 (2.37-2.93 mmol/L)
Number of subjects: 209

Group type: COMPARATOR
Intervention: LDL-C Q4 (>2.93 mmol/L)
Number of subjects: 209
Study: 37643848

Group type: EXPERIMENTAL
Intervention: Plasma biomarkers (intestinal fatty acid-binding protein, villin-1, smooth muscle protein 22-alpha) assessed by ELISA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) in exhaled air analyzed by gas chromatography time-of-flight mass spectrometry
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diagnosis of AMI based on CT, endovascular and surgical reports, clinical findings, and histopathological examination if applicable
Number of subjects: 120
Study: 37643847

Group type: EXPERIMENTAL
Intervention: IPL combined with 3% diquafosol ophthalmic solution (IPL+)
Number of subjects: 360

Group type: COMPARATOR
Intervention: IPL (active control group)
Number of subjects: 360

Group type: COMPARATOR
Intervention: DQS (3% diquafosol ophthalmic solution eye-drops) (active control group)
Number of subjects: 360
Study: 37643887

Group type: EXPERIMENTAL
Intervention: 4,500 mg of IV semorinemab every 4 weeks for 48 or 60 weeks
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 37643916

Group type: EXPERIMENTAL
Intervention: Move For Surgery (MFS) program, a home-based and wearable technology-enhanced preconditioning program before lung cancer surgery.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual preoperative care (Control group).
Number of subjects: 102
Study: 37644032

Group type: EXPERIMENTAL
Intervention: Deep learning-based approach for automating the Fleischner Society's visual score system for emphysema subtyping and severity analysis.
Number of subjects: 9650
Study: 37644215

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Standardized self-rating questionnaires on depressive and somatic symptoms
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Clinician ratings obtained within structured clinical interviews
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Multiomic analyses (genotyping, epigenetics, RNA sequencing, neuron-derived exosomes, purines, immunometabolics)
Number of subjects: 134
Study: 37644233

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine (ISA)
Number of subjects: 360
Study: 37644354

Group type: EXPERIMENTAL
Intervention: BRIGHT (brief cognitive behavioral therapy)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 44
Study: 37644356

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 73
Study: 37644510

Group type: EXPERIMENTAL
Intervention: Video triage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telephone triage
Number of subjects: 100
Study: 37644542

Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Hysteroscopic septoplasty
Number of subjects: 165
Study: 37644556

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg IV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 37644573

Group type: EXPERIMENTAL
Intervention: Preoperative coronary computed tomographic angiography (CCTA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard of care (angiography)
Number of subjects: 130
Study: 37644651

Group type: EXPERIMENTAL
Intervention: Turtle Program
Number of subjects: 151

Group type: COMPARATOR
Intervention: Cool Little Kids program (CLK)
Number of subjects: 151
Study: 37644732

Group type: EXPERIMENTAL
Intervention: Metabolic tumor volume (MTV) measured using fixed thresholds of SUV
Number of subjects: 0
Study: 37644779

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 3802

Group type: COMPARATOR
Intervention: No tolvaptan use
Number of subjects: 3802
Study: 37644869

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol/betamethasone in combination with NBUVB
Number of subjects: 0
Study: 37644980

Group type: EXPERIMENTAL
Intervention: Intradialytic regional cerebral oxygenation (rSO2) monitoring during the first 72 hours of continuous kidney replacement therapy or throughout each session of intermittent hemodialysis.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Delirium screening and neurocognitive impairment assessment using the Kinarm robot.
Number of subjects: 11
Study: 37645234

Group type: EXPERIMENTAL
Intervention: Community-based exercise program integrating a healthcare-community partnership (CBEP-HCP) delivered by trained fitness instructors over 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Community-based exercise program integrating a healthcare-community partnership (CBEP-HCP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Costs associated with first-time program implementation
Number of subjects: 20
Study: 37645440

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led intervention for drug-related problems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 37645455

Group type: EXPERIMENTAL
Intervention: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
Number of subjects: 12
Study: 37645472

Group type: EXPERIMENTAL
Intervention: At-home cognitive training tool (NeuroTrackerX) with 10 training sessions over 5 weeks (two times per week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: In-lab 3D-MOT program (control group) with 20 participants (10 female; mean age = 63.39 years, SD = 12.22)
Number of subjects: 20
Study: 37645519

Group type: EXPERIMENTAL
Intervention: Home-Based Teleassistance and Teleconsultation (HBTT) program for three months, including monitoring of vital signs and symptoms.
Number of subjects: 422

Group type: COMPARATOR
Intervention: Usual care (non-HBTT group)
Number of subjects: 422
Study: 37645544

Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBAP)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Right ventricular pacing (RVP)
Number of subjects: 903
Study: 37645622

Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine at 170 mg/m²
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine at 100 mg/m²
Number of subjects: 9
Study: 37645623

Group type: EXPERIMENTAL
Intervention: GTX-CI (gemcitabine, docetaxel, capecitabine, cisplatin, and irinotecan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GTX-C (gemcitabine, docetaxel, capecitabine, and cisplatin)
Number of subjects: 0
Study: 37645852

Group type: EXPERIMENTAL
Intervention: Non-invasive optical coherence tomography (OCT) imaging of the eye
Number of subjects: 23
Study: 37645940

Group type: EXPERIMENTAL
Intervention: Remote telehealth Transitional Pain Service (TPS) with opioid-tapering CBT protocol
Number of subjects: 86
Study: 37646126

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 2583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2583
Study: 37646138

Group type: EXPERIMENTAL
Intervention: Continuous exercise (5 minutes high intensity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-interval exercise (15 minutes high/moderate intervals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0
Study: 37646148

Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (prophylaxis)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (on-demand treatment)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rurioctocog alfa pegol (for immune tolerance induction)
Number of subjects: 80
Study: 37646208

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 3298

Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Number of subjects: 3298
Study: 37646214

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair with the MitraClip device plus maximally tolerated guideline-directed medical therapy (GDMT)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 383
Study: 37646262

Group type: EXPERIMENTAL
Intervention: Lactation support provided through WhatsApp
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 129
Study: 37646398

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37646619

Group type: EXPERIMENTAL
Intervention: Walking intensity preference intervention, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 37646657

Group type: EXPERIMENTAL
Intervention: Melflufen 30 mg plus dexamethasone and daratumumab
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Melflufen 40 mg plus dexamethasone and daratumumab
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone and bortezomib
Number of subjects: 56
Study: 37646659

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (in patients with CR)
Number of subjects: 145
Study: 37646661

Group type: EXPERIMENTAL
Intervention: Cyclin D1 protein detection
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein detection
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclin D1 protein high levels
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein detection in t(14;16) cases
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein detection in t(4;14) cases
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclin D2 presence
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclin D2 protein without 1q gains
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclin D1 and D2 protein undetectability
Number of subjects: 165
Study: 37646660

Group type: EXPERIMENTAL
Intervention: Melflufen plus daratumumab and dexamethasone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Daratumumab
Number of subjects: 54
Study: 37646664

Group type: EXPERIMENTAL
Intervention: Tafasitamab and lenalidomide
Number of subjects: 80
Study: 37646670

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed, 4-1BB CAR T-cell product administered at a total target dose of 100×10⁶ CAR+ T cells.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 56
Study: 37646671

Group type: EXPERIMENTAL
Intervention: Lenalidomide-R-CHOP followed by R-HiDAC and R-lenalidomide
Number of subjects: 49
Study: 37646676

Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis for at least 32 weeks (group 2)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis for at least 24 weeks (groups 3 and 4)
Number of subjects: 133

Group type: COMPARATOR
Intervention: No prophylaxis for at least 24 weeks (group 1)
Number of subjects: 133
Study: 37646677

Group type: EXPERIMENTAL
Intervention: Surgery at 6 months of age
Number of subjects: 558

Group type: COMPARATOR
Intervention: Surgery at 12 months of age
Number of subjects: 558
Study: 37646678

Group type: EXPERIMENTAL
Intervention: P85-Ab
Number of subjects: 24852

Group type: COMPARATOR
Intervention: Two-antibody method (EBNA1-IgA and VCA-IgA)
Number of subjects: 24852

Group type: EXPERIMENTAL
Intervention: Combination of P85-Ab and two-antibody method
Number of subjects: 24852
Study: 37646679

Group type: EXPERIMENTAL
Intervention: OTQ923 (CRISPR-Cas9-edited CD34+ HSPC product)
Number of subjects: 3
Study: 37646702

Group type: EXPERIMENTAL
Intervention: Mezigdomide plus dexamethasone (1.0 mg once daily for 21 days, followed by 7 days off, in each 28-day cycle)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Mezigdomide plus dexamethasone
Number of subjects: 101
Study: 37646865

Group type: EXPERIMENTAL
Intervention: Novel cell death tracer
Number of subjects: 6
Study: 37646988

Group type: EXPERIMENTAL
Intervention: 8000 IU daily with a loading dose of 50,000 IU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care control dose (600 IU daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loading dose of 50,000 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body mass index z-score
Number of subjects: 0
Study: 37647070

Group type: EXPERIMENTAL
Intervention: LCSDecTool
Number of subjects: 140

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 140
Study: 37647105

Group type: EXPERIMENTAL
Intervention: Minder app (intervention group)
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Waitlist control group (control group)
Number of subjects: 1496
Study: 37647138

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37647156

Group type: EXPERIMENTAL
Intervention: Biomaterial-enhanced secondary intention healing (SIH)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard secondary intention healing (SIH)
Number of subjects: 37
Study: 37647305

Group type: EXPERIMENTAL
Intervention: Standard Technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doppler Ultrasonography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressure Waveform Analysis
Number of subjects: 0
Study: 37647317

Group type: EXPERIMENTAL
Intervention: VRVF device (self-administered remote visual field monitoring)
Number of subjects: 21
Study: 37647517

Group type: EXPERIMENTAL
Intervention: Relative household overcrowding
Number of subjects: 3679

Group type: EXPERIMENTAL
Intervention: Black, Black British, Caribbean, or African ethnicity
Number of subjects: 3679

Group type: EXPERIMENTAL
Intervention: Increasing age (ages 50-60 years)
Number of subjects: 3679

Group type: EXPERIMENTAL
Intervention: Lack of access to sick pay
Number of subjects: 3679
Study: 37647576

Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus gemcitabine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 82
Study: 37647601

Group type: EXPERIMENTAL
Intervention: Vibecotamab (XmAb14045) at a target dose of 0.75 μg/kg or higher (n=87)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vibecotamab (XmAb14045)
Number of subjects: 120
Study: 37647633

Group type: EXPERIMENTAL
Intervention: CD24Fc multidose regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls (placebo)
Number of subjects: 0
Study: 37647647

Group type: EXPERIMENTAL
Intervention: CAR T-cell product targeting CD19 and CD22
Number of subjects: 12
Study: 37647728

Group type: EXPERIMENTAL
Intervention: TQB2450 plus anlotinib 10 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TQB2450 plus anlotinib 12 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: TQB2450 plus placebo
Number of subjects: 101
Study: 37648112

Group type: EXPERIMENTAL
Intervention: Biofortified potatoes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular potatoes
Number of subjects: 0
Study: 37648263

Group type: EXPERIMENTAL
Intervention: CD39 expression in tumor tissue among NK cells, fibroblasts, and T cells
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: CD73 expression in tumor tissue among fibroblasts and Epcam+ cells
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Density of CD39+CD103+CD8+ T cells in tumor nest
Number of subjects: 162
Study: 37648345

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using new-generation transcatheter heart valves (THVs)
Number of subjects: 201
Study: 37648379

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (RBCT)
Number of subjects: 65
Study: 37648382

Group type: EXPERIMENTAL
Intervention: Second-line therapy
Number of subjects: 519
Study: 37648383

Group type: EXPERIMENTAL
Intervention: 2 g azithromycin
Number of subjects: 34000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34000
Study: 37648393

Group type: EXPERIMENTAL
Intervention: Antenatal and intrapartum azithromycin
Number of subjects: 49600

Group type: EXPERIMENTAL
Intervention: Azithromycin administered concurrently with the first and third doses of pentavalent vaccines (Penta-1/3)
Number of subjects: 49600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49600
Study: 37648417

Group type: EXPERIMENTAL
Intervention: Short oral/two-step consent (SOC)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Deferred consent (DC)
Number of subjects: 108
Study: 37648439

Group type: EXPERIMENTAL
Intervention: FACETS+ plus standard care
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 105